Oxford Gene Technology SureSeq Myeloid MRD panel
Oxford Gene Technology has launched its new next-generation sequencing-based SureSeq Myeloid MRD panel in North America. The test provides a flexible NGS workflow for the detection of ultra-low frequency biomarkers of measurable residual disease in acute myeloid leukemia.These include the largest and most complex AML-associated variants in key genes, such as large FLT3 internal tandem duplications, that often go undetected by previous generations of PCR-based enrichment technologies. OGT said its MRD panel targets 45 hotspot exons in 13 genes, with mean target coverage of up to 20,000X.